A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*
- 1 June 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 37 (6), 2071-2078
- https://doi.org/10.1097/ccm.0b013e3181a0054d
Abstract
The clinical benefits of extended infusion or continuous infusion of β-lactam antibiotics remain controversial. We systematically reviewed the literature to determine whether any clinical benefits exist for administration of β-lactam antibiotics by extended or continuous infusion. PubMed (January 1950 to November 2007), EMBASE (1966 to November 2007), and the Cochrane Controlled Trial Register were searched (updated November 2007). Randomized controlled trials (RCTs) were meta-analyzed, and observational studies were described by two unblinded reviewers. A total of 846 patients from eligible prospective randomized controlled studies were included in the meta-analysis. Two observational studies were deemed appropriate for description. A meta-analysis of prospective RCTs was undertaken using Review Manager. Among a total of 59 potentially relevant studies, 14 RCTs involving a total of 846 patients from nine countries were deemed appropriate for meta-analysis. The use of continuous infusion of a β-lactam antibiotic was not associated with an improvement in clinical cure (n = 755 patients; odds ratio: 1.04, 95% confidence interval: 0.74-1.46, p = 0.83, I2 = 0%) or mortality (n = 541 patients; odds ratio: 1.00, 95% confidence interval: 0.48-2.06, p = 1.00, I2 = 14.8%). All RCTs except one used a higher antibiotic dose in the bolus administration group. Two observational studies, not pooled because they did not meet the a priori criteria for meta-analysis, showed that β-lactam administration by extended or continuous infusion was associated with an improvement in clinical cure. The difference in the results between the meta-analysis results and the observational studies could be explained by the bias created by a higher dose of antibiotic in the bolus group in the RCTs and because many of the RCTs only recruited patients with a low acuity of illness. The limited data available suggest that continuous infusion of β-lactam antibiotics leads to the same clinical results as higher dosed bolus administration in hospitalized patients.Keywords
This publication has 65 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled TrialAntimicrobial Agents and Chemotherapy, 2007
- Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal InfectionAntimicrobial Agents and Chemotherapy, 2006
- Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)Diagnostic Microbiology and Infectious Disease, 2006
- Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacyBritish Journal of Clinical Pharmacology, 2006
- Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infectionJournal of Antimicrobial Chemotherapy, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemiaJournal of Pharmacy and Pharmacology, 2002
- Antimicrobial resistance issues of the futureDiagnostic Microbiology and Infectious Disease, 1996
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- Treatment of gram-negative bacillary septicemia with cefoperazoneEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983